Reports

As the novel coronavirus (COVID-19) continues to spread across the world, our analysts are constantly tracking the impact of this rapidly evolving situation on the markets and the consumer purchase behaviours. Thus, our latest estimates and analysis about the current market trends and forecast will exhaustively reflect the effects of this emerging pandemic.

Global Acute Lymphocytic/Lymphoblastic Leukaemia (ALL) Therapeutics Market: By Cell Type: B-cell ALL, T-cell ALL, Philadelphia chromosome: Positive (Ph+) and negative (Ph-) ALL; By Therapy Type; Regional Analysis; Historical Market and Forecast (2016-2026); Market Dynamics; Competitive Landscape; Industry Events and Developments

Global Acute Lymphocytic/Lymphoblastic Leukaemia (ALL) Therapeutics Market Outlook

The global acute lymphocytic/lymphoblastic leukaemia (ALL) therapeutics market attained a value of USD 2.44 billion in 2020. The market is further expected to grow in the forecast period of 2021-2026 at a CAGR of 4.6% to reach USD 3.2 billion by 2026.

 

Global Acute Lymphocytic/Lymphoblastic Leukaemia (ALL) Therapeutics Market

Read more about this report - REQUEST FREE SAMPLE COPY IN PDF

 

The rising occurrence of acute lymphoblastic leukaemia (ALL) and the growing initiatives by public and private organisations are among the key factors anticipated to drive the market growth.

 

Properties and Applications

The acute lymphocytic/lymphoblastic leukaemia (ALL) therapeutics industry can be broadly categorised based on cell type and therapy type.

 

Global Acute Lymphocytic/Lymphoblastic Leukaemia (ALL) Therapeutics Market By Therapy Type

Read more about this report - REQUEST FREE SAMPLE COPY IN PDF

 

Based on cell type, the market is segmented into:

  • B-Cell ALL 
  • T-Cell ALL 
  • Philadelphia Chromosome: Positive (Ph+) and Negative (Ph-) ALL

Based on the therapy type, the market is divided into:

  • Chemotherapy
    • Hyper- CVAD Regimen
    • CALGB 8811 Regimen
    • Linker Regimen
    • Nucleoside Inhibitors
    • Others
  • Targeted Therapy
  • Radiation Therapy
  • Stem Cell Transplantation

The EMR report looks into the regional markets of acute lymphocytic/lymphoblastic leukaemia (ALL) therapeutics like North America, Latin America, Europe, the Middle East and Africa, and the Asia Pacific.

 

Global Acute Lymphocytic/Lymphoblastic Leukaemia (ALL) Therapeutics Market By Region

Read more about this report - REQUEST FREE SAMPLE COPY IN PDF

 

Market Analysis

The technological progress made in the identification of infected cells is a significant market growth driver. Due to factors such as the capacity to kill leukaemia cells and the prevention of the growth and proliferation of cancer, the chemotherapy segment was leading the market in 2020. Due to the growing prevalence in adults, the B-cell ALL type is projected to be the fastest-growing category in the industry. With the release of Besponsa (inotuzumab ozogamicin) and pipeline drugs such as eryaspase (asparaginase), the United States is anticipated to witness a significant growth in the industry in the coming years.

 

Competitive Landscape

The report presents a detailed analysis of the following key players in the global acute lymphocytic/lymphoblastic leukaemia (ALL) therapeutics industry, looking into their capacity, market shares, and latest developments like capacity expansions, plant turnarounds, and mergers and acquisitions:

  • Bristol-Myers Squibb (NYSE: BMY)
  • Celgene Corporation
  • Eisai Co Ltd
  • ERYTECH Pharma.
  • F. Hoffmann-La Roche AG
  • Genmab A/S 
  • GlaxoSmithKline plc
  • Novartis International AG
  • Pfizer Inc.
  • Sanofi SA
  • SymBio Pharmaceuticals Limited
  • Others

The EMR report gives an in-depth insight into the market by providing a SWOT analysis as well as an analysis of Porter’s Five Forces model.

 

REPORT FEATURES DETAILS
Base Year 2020
Historical Period 2016-2020
Forecast Period 2021-2026
Scope of the Report Historical and Forecast Trends, Industry Drivers and Constraints, Historical and Forecast Market Analysis by Segment- Cell Type, Therapy Type, Region
Breakup by Cell Type B-cell ALL, T-cell ALL, Philadelphia chromosome: Positive (Ph+) and negative (Ph-) ALL
Breakup by Therapy Type Chemotherapy, Targeted Therapy, Radiation Therapy, Stem Cell Transplantation
Breakup by Region North America, Europe, Asia Pacific, Latin America, Middle East and Africa
Market Dynamics SWOT, Porter's Five Forces, EMR’s Key Indicators for Price and Demand
Competitive Landscape Market Structure, Company Profiles- Company Overview, Product Portfolio, Demographic Reach and Achievements, Certifications
Companies Covered Bristol-Myers Squibb, BMY (NYSE), Celgene Corporation, CELG (NASDAQ),
Eisai Co Ltd, 4523 (TYO), ERYTECH Pharma. , ERYP (EPA), F. Hoffmann-La
Roche AG, ROG (SWX), Genmab A/S , GMAB (CPH), GlaxoSmithKline plc,
GSK (LON), Novartis International AG ,NOVN (SWX), Pfizer Inc., PFE (NYSE),
Sanofi SA, SAN (EPA), SymBio Pharmaceuticals Limited, Others
Report Price and Purchase Option Explore our purchase options that are best suited to your resources and industry needs.
Delivery Format Delivered as an attached PDF and Excel through email, with an option of receiving an editable PPT, according to the purchase option.

 

*We at Expert Market Research always thrive to give you the latest information. The numbers in the article are only indicative and may be different from the actual report.

1    Preface
    1.1    Objectives of the Study
    1.2    Key findings of the Study
2    Research Methodology
    2.1    Data Extraction
    2.2    Data Corroboration
    2.3    Market Structure
    2.4    Inference Data
3    Executive Summary
    3.1    Market Overview
    3.2    Market Analysis
4    Global Acute Lymphocytic/Lymphoblastic Leukaemia (ALL) Therapeutics Market 
    4.1    Global Acute Lymphocytic/Lymphoblastic Leukaemia (ALL) Therapeutics Historical Market (2016-2020) & Forecast (2021-2026)
    4.2    Global Acute Lymphocytic/Lymphoblastic Leukaemia (ALL) Therapeutics Market Breakup by Cell Type
        4.2.1    B-cell ALL 
        4.2.2    T-cell ALL 
        4.2.3    Philadelphia chromosome: Positive (Ph+) and negative (Ph-) ALL 
    4.3    Global Acute Lymphocytic/Lymphoblastic Leukaemia (ALL) Therapeutics Market Breakup by Cell Type: Historical Market (2016-2020) & Forecast (2021-2026)
        4.3.1    B-cell ALL 
        4.3.2    T-cell ALL 
        4.3.3    Philadelphia chromosome: Positive (Ph+) and negative (Ph-) ALL 
    4.4    Global Acute Lymphocytic/Lymphoblastic Leukaemia (ALL) Therapeutics Market Breakup by Therapy Type           
        4.4.1    Chemotherapy
            4.4.1.1    Hyper- CVAD Regimen
            4.4.1.2    CALGB 8811 Regimen
            4.4.1.3    Linker Regimen
            4.4.1.4    Nucleoside Inhibitors
            4.4.1.5    Others
        4.4.2    Targeted Therapy
        4.4.3    Radiation Therapy
        4.4.4    Stem Cell Transplantation
    4.5    Global Acute Lymphocytic/Lymphoblastic Leukaemia (ALL) Therapeutics Market Breakup by Therapy Type: Historical Market (2016-2020) & Forecast (2021-2026)
        4.5.1    Chemotherapy
            4.5.1.1    Hyper- CVAD Regimen
            4.5.1.2    CALGB 8811 Regimen
            4.5.1.3    Linker Regimen
            4.5.1.4    Nucleoside Inhibitors
            4.5.1.5    Others
        4.5.2    Targeted Therapy
        4.5.3    Radiation Therapy
        4.5.4    Stem Cell Transplantation
    4.6    Global Acute Lymphocytic/Lymphoblastic Leukaemia (ALL) Therapeutics Market Breakup by Region
        4.6.1    North America
            4.6.1.1    United States of America
            4.6.1.2    Canada
        4.6.2    Europe
            4.6.2.1    Germany
            4.6.2.2    United Kingdom
            4.6.2.3    France
            4.6.2.4    Italy
            4.6.2.5    Others
        4.6.3    Asia Pacific
            4.6.3.1    China
            4.6.3.2    Japan
            4.6.3.3    India
            4.6.3.4    ASEAN
            4.6.3.5    Others
        4.6.4    Latin America
            4.6.4.1    Brazil
            4.6.4.2    Argentina
            4.6.4.3    Mexico
            4.6.4.4    Others
        4.6.5    Middle East & Africa
            4.6.5.1    Saudi Arabia
            4.6.5.2    United Arab Emirates
            4.6.5.3    Nigeria
            4.6.5.4    South Africa
            4.6.5.5    Others
    4.7     Global Acute Lymphocytic/Lymphoblastic Leukaemia (ALL) Therapeutics Market Breakup by Region: Historical Market (2016-2020) & Forecast (2021-2026)
        4.7.1    North America
            4.7.1.1    United States of America
            4.7.1.2    Canada
        4.7.2    Europe
            4.7.2.1    Germany
            4.7.2.2    United Kingdom
            4.7.2.3    France
            4.7.2.4    Italy
            4.7.2.5    Others
        4.7.3    Asia Pacific
            4.7.3.1    China
            4.7.3.2    Japan
            4.7.3.3    India
            4.7.3.4    ASEAN
            4.7.3.5    Others
        4.7.4    Latin America
            4.7.4.1    Brazil
            4.7.4.2    Argentina
            4.7.4.3    Mexico
            4.7.4.4    Others
        4.7.5    Middle East & Africa
            4.7.5.1    Saudi Arabia
            4.7.5.2    United Arab Emirates
            4.7.5.3    Nigeria
            4.7.5.4    South Africa
            4.7.5.5    Others
5    SWOT Analysis
    5.1    Overview
    5.2    Strengths
    5.3    Weaknesses
    5.4    Opportunities
    5.5    Threats
6    Porter’s Five Forces Analysis
    6.1    Overview
    6.2    Buyer’s Power
    6.3    Supplier’s Power
    6.4    New Entrants
    6.5    Degree of Rivalry
    6.6    Substitutes
7    Key Players & Company Profile Analysis
    7.1    Bristol-Myers Squibb, BMY (NYSE)
    7.2    Celgene Corporation, CELG (NASDAQ)
    7.3    Eisai Co Ltd, 4523 (TYO)
    7.4    ERYTECH Pharma. , ERYP (EPA)
    7.5    F. Hoffmann-La Roche AG, ROG (SWX)
    7.6    Genmab A/S , GMAB (CPH)
    7.7    GlaxoSmithKline plc, GSK (LON)
    7.8    Novartis International AG ,NOVN (SWX)
    7.9    Pfizer Inc., PFE (NYSE)
    7.10    Sanofi SA, SAN (EPA)
    7.11    SymBio Pharmaceuticals Limited
    7.12    Others
8    Industry Events and Developments

Key Questions Answered in the Report

In 2020, the global acute lymphocytic/lymphoblastic leukaemia (ALL) therapeutics market attained a value of nearly USD 2.44 billion.

The market is projected to grow at a CAGR of 4.6% between 2021 and 2026.

The market is estimated to witness a healthy growth in the forecast period of 2021-2026 to reach about USD 3.2 billion by 2026.

The major drivers of the industry, such as the growing incidences of acute lymphoblastic leukaemia, initiatives by various public and private organisations to create awareness among people, growing R&D activities, and rapid technological advancements, are expected to aid the market growth.

The development of inotuzumab ozogamicin (Besponsa) and pipeline drugs is the key market trend guiding the growth of the industry.

The major regions in the industry are North America, Latin America, the Middle East and Africa, Europe, and the Asia Pacific.

B-cell ALL, T-cell ALL, and Philadelphia chromosome- positive (Ph+) and -negative (Ph-) ALL are the significant cell types of acute lymphocytic/lymphoblastic leukaemia (ALL) therapeutics in the industry.

Chemotherapy segment is the leading therapy type in the market.

The major players in the industry are Bristol-Myers Squibb, Celgene Corporation, Eisai Co Ltd, ERYTECH Pharma., F. Hoffmann-La Roche AG, Genmab A/S, GlaxoSmithKline plc, Novartis International AG, Pfizer Inc., Sanofi SA, and SymBio Pharmaceuticals Limited, among others.

Analyst Review

The global acute lymphocytic/lymphoblastic leukaemia (ALL) therapeutics market attained a value of USD 2.44 billion in 2020, driven by the growing cases of acute lymphoblastic leukaemia and increased clinical trials. Aided by the development of inotuzumab ozogamicin, the market is expected to witness a further growth in the forecast period of 2021-2026, growing at a CAGR of 4.6%. The industry is projected to reach USD 3.2 billion by 2026.

EMR’s meticulous research methodology delves deep into the market, covering the macro and micro aspects of the industry. Based on cell type, the industry can be segmented into B-cell ALL, T-cell ALL, and Philadelphia chromosome- positive (Ph+) and -negative (Ph-) ALL. On the basis of therapy, the chemotherapy segment accounts for the leading share in the industry. The major regional markets for acute lymphocytic/lymphoblastic leukaemia (ALL) therapeutics are North America, Europe, the Asia Pacific, Latin America, and the Middle East and Africa. The key players in the above market include Bristol-Myers Squibb, Celgene Corporation, Eisai Co Ltd, ERYTECH Pharma., F. Hoffmann-La Roche AG, Genmab A/S, GlaxoSmithKline plc, Novartis International AG, Pfizer Inc., Sanofi SA, SymBio Pharmaceuticals Limited, and others.

EMR’s research methodology uses a combination of cutting-edge analytical tools and the expertise of their highly accomplished team, thus, providing their customers with market insights that are accurate, actionable, and help them remain ahead of their competition.

Purchase Full Report

Mini Report

$1499
  • Selected Sections, One User
  • Printing Not Allowed
  • Email Delivery in PDF
  • Free Limited Customisation
  • Post Sales Analyst Support
  • 50% Discount on Next Update

Single User License

$2699
  • All Sections, One User
  • One Print Allowed
  • Email Delivery in PDF
  • Free Limited Customisation
  • Post Sales Analyst Support
  • 50% Discount on Next Update

Five User License

$3699
  • All Sections, Five Users
  • Five Prints Allowed
  • Email Delivery in PDF
  • Free Limited Customisation
  • Post Sales Analyst Support
  • 50% Discount on Next Update

Corporate License

$4699
  • All Sections, Unlimited Users
  • Unlimited Prints Allowed
  • Email Delivery in PDF + Excel
  • Free Limited Customisation
  • Post Sales Analyst Support
  • 50% Discount on Next Update

Any Question? Speak With An Analyst

Contact Analyst

View A Sample

Request Sample

Did You Miss Anything, Ask Now

Request Customisation
Why Expert Market Research?

RIGHT PEOPLE

We are technically excellent, strategic, practical, experienced and efficient; our analysts are hand-picked based on having the right attributes to work successfully and execute projects based on your expectations.

RIGHT METHODOLOGY

We leverage our cutting-edge technology, our access to trusted databases, and our knowledge of the current models used in the market to deliver you research solutions that are tailored to your needs and put you ahead of the curve.

RIGHT PRICE

We deliver in-depth and superior quality research in prices that are reasonable, unmatchable, and shows our understanding of your resource structure. We, additionally, offer attractive discounts on our upcoming reports.

RIGHT SUPPORT

Our team of expert analysts are at your beck and call to deliver you optimum results that are customised to meet your precise needs within the specified timeframe and help you form a better understanding of the industry.

Similar Reports





NEWSLETTER